28
Oct
2025

Coripharma

Exhibitor at CPHI Frankfurt 2025 stand 3.0G62, Finished Dosage Formulations
About Us

Coripharma is an established European generic pharmaceutical company with a powerful heritage. 

We offer out-licensing of our own developed products as well as contract manufacturing to generic pharmaceutical companies demanding high quality services from a reliable European partner.

Coripharma was founded in 2018, but our dynamic team draws from decades of knowledge and experience in the pharmaceutical industry. Our manufacturing site is located on Iceland’s southern peninsula and has been a pillar in our ...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • IS
  • 2020
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company
View company profile
Contact info
  • 7729606
  • Website
  • Reykjavikurvegur 78 - 80, 220, Hafnarfjordur, Iceland
Show contact info Hide contact info
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 3.0G62, Finished Dosage Formulations

Products Featured at CPHI Frankfurt 2025

  • Ruxolitinib

    Product Ruxolitinib

    Ruxolitinib is used for the treatment of symptoms in adult patients with primary myelofibrosis which is a rare form of blood cancer. Ruxolitinib tablets come in four strengths, 5 mg, 10 mg, 15 mg and 20 mg. Pivotal BE study is completed and passing. Dossier is available and DCP slot confirmed in January 20...
  • Coripharma Dossier List

    Product Coripharma Dossier List

    We offer out-licensing of our own developed dossiers, along with a range of services that enable our customers to take products to their respective markets at the date of patent expiry and under their own brand. Currently we have over 20 own developed dossiers on our pipeline and our dossier list is readil...
  • Macitentan

    Product Macitentan

    Macitentan is a medicine that is used to treat Pulmonary arterial hypertension. Macitentan Film-coated tablets has one strength, 10mg, has passed its pivotal bioequivalence study and dossier is available.
    Our business development team remains available to discuss opportunities with our customers.
    ...
  • Eliglustat

    Product Eliglustat

    Is used to treat Gaucher disease which is a fat storage disorder. Eliglustat is available in 84mg hard capsules. Coripharma`s generic version of Eliglustat is being developed in our R&D facility located in Iceland, which is run solely on sustainable energy. We plan to have the dossier available in Q1 2...
  • Lisdexamfetamine

    Product Lisdexamfetamine

    Lisdexamfetamine is used to treat ADHD in children and adults. Lisdexamfetamine capsules come in six strengths, 20mg, 30mg, 40mg, 50mg, 60mg and 70mg. Pivotal BE study is completed and passing. Coripharma will finalize the dossier in Q4 2024 and start submitting for our clients in January 2025.